eligibility_summary
Eligibility: advanced mesothelin-positive cancer, >12-week life expectancy, adequate heart/lung/liver/kidney/blood function, available autologous Mesothelin-CAR T cells (≥20% CAR expression and ≥20% cytotoxicity), informed consent. Exclude prior gene therapy, active infections (HBV/HCV/HIV/bacterial/fungal), severe comorbidities, pregnancy/lactation, systemic steroids ≥0.5 mg/kg/day, investigator judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Autologous, second-generation CAR-T cell therapy targeting mesothelin (biological/adoptive cell immunotherapy). The CAR-Ts are engineered to secrete an IL-21–anti-PD-1 scFv fusion protein, providing localized cytokine support and checkpoint blockade to enhance T-cell activation, proliferation, persistence, and tumor cytotoxicity. Optional co-treatment with systemic PD-1/PD-L1 or CTLA-4 antibodies may be used. Targets/pathways: mesothelin on tumor cells, PD-1/PD-L1 and CTLA-4 immune checkpoints, IL-21 signaling in T cells. Indication: mesothelin-positive pancreatic and other solid tumors.